GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Apellis Pharmaceuticals Inc (STU:1JK) » Definitions » Common Stock

Apellis Pharmaceuticals (STU:1JK) Common Stock : €0.0 Mil (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Apellis Pharmaceuticals Common Stock?

Apellis Pharmaceuticals's quarterly common stock stayed the same from Mar. 2024 (€0.0 Mil) to Jun. 2024 (€0.0 Mil) and stayed the same from Jun. 2024 (€0.0 Mil) to Sep. 2024 (€0.0 Mil).

Apellis Pharmaceuticals's annual common stock increased from Dec. 2021 (€0.0 Mil) to Dec. 2022 (€0.0 Mil) and increased from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€0.0 Mil).


Apellis Pharmaceuticals Common Stock Historical Data

The historical data trend for Apellis Pharmaceuticals's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Apellis Pharmaceuticals Common Stock Chart

Apellis Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Common Stock
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Apellis Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Apellis Pharmaceuticals Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Apellis Pharmaceuticals Business Description

Traded in Other Exchanges
Address
100 Fifth Avenue, Waltham, MA, USA, 02451
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.

Apellis Pharmaceuticals Headlines

No Headlines